SOCRA Adverse Event Safety Reporting 3 — Questions and Answers
Question 1: In a blinded clinical trial, when is it permissible to break the blind for a subject who experiences an SAE?
- Only after the trial is complete
- Only when necessary for appropriate medical management of the subject (Correct answer)
- Whenever the investigator requests it
- Only with prior IRB/IEC approval in each instance
Correct answer: Only when necessary for appropriate medical management of the subject
The blind should only be broken when clinically necessary for the appropriate medical management of the patient, not for administrative or reporting convenience.
Question 2: What is the primary purpose of the CIOMS I form in clinical research safety reporting?
- Documenting protocol deviations for IRB review
- Reporting individual case safety reports (ICSRs) to regulatory authorities internationally (Correct answer)
- Enrolling new subjects after a safety hold is lifted
- Recording annual aggregate safety data for the DSUR
Correct answer: Reporting individual case safety reports (ICSRs) to regulatory authorities internationally
The CIOMS I form is an internationally recognized format for expedited reporting of individual case safety reports (ICSRs) to regulatory authorities.
Question 3: When a sponsor unblocks treatment assignment to assess causality for an SAE, who should ideally remain blinded to preserve trial integrity?
- The sponsor's pharmacovigilance safety team
- The regulatory authority receiving the report
- Investigators and study site staff not involved in medical management (Correct answer)
- The institutional review board reviewing the protocol
Correct answer: Investigators and study site staff not involved in medical management
To protect trial integrity and minimize bias, investigators and staff not involved in direct medical management of the SAE should remain blinded whenever possible.
Question 4: The Development Safety Update Report (DSUR) is designed to:
- Report individual SAEs within 15 days of occurrence
- Provide a comprehensive annual review of an investigational product's safety profile during clinical development (Correct answer)
- Submit protocol amendments to regulatory authorities
- Replace the Investigator's Brochure after each trial phase
Correct answer: Provide a comprehensive annual review of an investigational product's safety profile during clinical development
The DSUR (per ICH E2F) is an annual cumulative safety report that summarizes all safety findings for an investigational product across all ongoing clinical trials.
Question 5: An investigator receives a sponsor safety letter reporting a new SAE from a different site using the same investigational drug. What is the investigator's primary obligation?
- Immediately withdraw all enrolled subjects from the trial
- Notify the IRB/IEC and assess implications for subjects currently enrolled at their site (Correct answer)
- File an independent report directly to the FDA
- Discard the letter as it pertains to another site
Correct answer: Notify the IRB/IEC and assess implications for subjects currently enrolled at their site
Investigators must forward relevant safety information to their IRB/IEC and consider whether the new safety data changes the risk-benefit assessment for subjects at their own site.
Question 6: Which of the following best describes a 'suspected adverse reaction' in the context of IND safety reporting?
- Any AE occurring after the first dose regardless of relationship
- An AE for which there is a reasonable possibility of a causal relationship to the investigational drug (Correct answer)
- An AE that is listed in the Investigator's Brochure as expected
- An AE that resolves without medical intervention
Correct answer: An AE for which there is a reasonable possibility of a causal relationship to the investigational drug
A suspected adverse reaction is any AE for which there is a reasonable possibility that the investigational drug caused the event, based on available evidence and clinical judgment.
Question 7: How should an investigator handle follow-up information after an initial SAE report is submitted to the sponsor?
- No follow-up is needed once the initial SAE form is submitted
- Follow-up reports must be submitted as new information becomes available until the event resolves or stabilizes (Correct answer)
- Follow-up reports are only required if the subject is hospitalized
- Follow-up is the sponsor's sole responsibility after the initial report
Correct answer: Follow-up reports must be submitted as new information becomes available until the event resolves or stabilizes
Investigators are responsible for submitting follow-up reports with updated information (e.g., lab results, outcome, causality reassessment) until the SAE resolves, stabilizes, or the subject exits the study.
SOCRA Adverse Event Safety Reporting 3
In a blinded clinical trial, when is it permissible to break the blind for a subject who experiences an SAE?